News

Fenwal said that its InterSol solution has been approved by the FDA in December 2009 under a new drug application. It is the platelet additive solution available in

Sigma Life Science said that the extension of its product offering, the first ever models created especially for ADME/Tox applications, is expected to help researchers establish the efficacy

The 708-DS supports a broad set of applications ranging from manual dissolution testing to automated, high-throughput analysis. Varian said that its 708-DS provides flexibility to match the needs

Isis claimed that ISIS-SOD1Rx is an anti-sense drug designed to restrict the production of SOD1. The ALS Association and the Muscular Dystrophy Association are providing funding for the

Ocrelizumab is also being evaluated for relapsing remitting multiple sclerosis (RRMS). The treatment in the Ocrelizumab RRMS Phase II study is on-going at this time. The DSMB concluded

The data were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), held March 5-7, 2010 in San Francisco, CA. TAK-700, discovered by Takeda,

The companies have earmarked an estimated total of $1.4bn for the expansion. They have begun the expansion at BYC in September 2009. According to Johnny Kwan, board chairman

Archexin is a potent inhibitor of Akt protein kinase in the treatment of cancer. Akt regulates signal processes of cell proliferation and survival, angiogenesis, and drug resistance in

Stentys said that the self-expanding feature of the platform is designed to ensure optimal apposition of a stent in the critical initial hours and days after an acute